Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

2.

Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?

Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J.

Am J Med. 2003 Dec 15;115(9):715-20.

PMID:
14693324
4.

"Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.

Bennett K, Teeling M, Feely J.

Eur J Clin Pharmacol. 2003 Nov;59(8-9):645-9. Epub 2003 Aug 27.

PMID:
12942226
5.
6.
7.

Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study.

Depont F, Fourrier A, Merlière Y, Droz C, Amouretti M, Bégaud B, Bénichou J, Moride Y, Velo GP, Sturkenboom M, Blin P, Moore N; CADEUS Team.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):891-900.

PMID:
17351983
8.

Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.

Landsberg PG, Pillans PI, Radford JM.

Intern Med J. 2003 May-Jun;33(5-6):225-8.

PMID:
12752891
9.
10.

Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.

Barozzi N, Tett SE.

Clin Ther. 2009 Apr;31(4):849-61. doi: 10.1016/j.clinthera.2009.04.012.

PMID:
19446158
11.
14.
15.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

16.

Prescriber adoption of newly approved selective COX-2 inhibitors.

Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AG.

Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1168-74. doi: 10.1002/pds.1667.

PMID:
18821717
17.

Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.

Shireman TI, Rigler SK.

Am J Geriatr Pharmacother. 2006 Sep;4(3):210-8.

PMID:
17062321
19.

Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs.

Langman MJ, Eichler HG, Mavros P, Watson DJ, Kong SX.

Int J Clin Pharmacol Ther. 2004 May;42(5):260-6.

PMID:
15176648
Items per page

Supplemental Content

Write to the Help Desk